What is ALT stock price today?

ALT (Altimmune Inc) stock is trading at $3.80 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ALT stock going up or down today?

ALT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ALT stock now?

The decision to buy ALT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ALT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ALT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ALT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ALT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ALT's P/E ratio?

P/E ratio data for ALT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ALT's market cap?

ALT (Altimmune Inc) has a market capitalization of $0.48 billion, making it a small-cap stock.

What is ALT's price to book ratio?

ALT trades at a price-to-book (P/B) ratio of 2.15, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ALT pay dividends?

ALT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ALT's dividend yield?

ALT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ALT stock a good long-term investment?

ALT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ALT's revenue growth rate?

ALT has shown revenue growth of 4.2% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ALT are available on our dashboard with complete income statement analysis.

What are the risks of investing in ALT?

Key risks for ALT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ALT compare to its competitors?

Compare ALT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ALT's performance and positioning.

What is ALT's stock price target for 2026?

Our AI model provides price targets for ALT based on fundamental analysis: Bull case $4.94 (+30%), Base case $4.37 (+15%), Bear case $3.42 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ALT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ALT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ALT's next earnings report?

ALT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ALT - Altimmune Inc

NYSE * Health Care * Biotechnology

$3.80

$-0.06 (-1.55%)

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

ALT Key Statistics

Market Cap

$483.39M

P/B Ratio

2.15

EPS

$-1.00

Revenue Growth

+4.2%

Employees

How ALT Compares to Peers

ALT has the fastest revenue growth among competitors

ALT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ALT(This stock)	$483.39M	N/A	4%	0.0%	-
AMGNAmgen Inc	$202.38B	26.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$184.43B	21.9	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$126.79B	32.6	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$81.62B	18.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.95B	21.4	-0%	0.1%	vs BIIB

Altimmune Inc Company Information

Headquarters: Maryland; U.S.A
Website: altimmune.com
Sector: Health Care
Industry: Biotechnology

Data Updated: March 12, 2026 at 8:01 PM EDT

Ready to invest in ALT?

Commission-free trading available. Affiliate links.

ALT Lician Score

10% confidence

4.0/10

Neutral

ALT has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

1.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ALTacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ALT Financial Snowflake

5-axis analysis across key investment dimensions

4.2/10

Neutral

5.0

Value

Valuation vs. sector peers

1.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for ALT

Dashboard

Enter a ticker to analyze